Developer Applies for Use of CAR T-Cell Therapy in DLBCL
Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
The pharmaceutical company Novartis has submitted an application to the US Food and Drug Administration (FDA) to extend the indications for its chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah). The application is for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.
“The data show this therapy could change the treatment paradigm for patients with relapsed/refractory DLBCL,” said Stephen Schuster, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, according to a
CAR T-cell therapies have started to gain approvals in recent months. Tisagenlecleucel was first
The new application for use in DLBCL is based on results of the phase II
“We’ve seen durable complete responses in patients who previously relapsed or were refractory to prior therapies, and this second filing is a significant step toward realizing its potential for even more patients who are currently battling fatal blood cancers,” Schuster said. The global head of drug development and chief medical officer for Novartis, Vas Narasimhan, added that the good response rates seen in the JULIET trial show the therapy “has the potential to transform treatment for these patients.”
CAR T-cell therapy involves tailoring the agent specifically to each patient. T cells are drawn from the patient, and then genetically modified to specifically target cancer cells. In other trials involving tisagenlecleucel, cytokine release syndrome (CRS) was a significant adverse effect; its previous approval included a
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025